<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941057</url>
  </required_header>
  <id_info>
    <org_study_id>13469</org_study_id>
    <secondary_id>2009-011963-35</secondary_id>
    <nct_id>NCT00941057</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium</brief_title>
  <official_title>Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV), Dienogest (DNG) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 2 mg Estradiol Valerate and 3 mg Dienogest Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) and Dienogest (DNG) after
      administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg Dienogest
      and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 2 mg
      Estradiol Valerate,3 mg Dienogest.Investigation of the bioequivalence of levomefolate calcium
      after administration of one film-coated tablet containing 2 mg Estradiol Valerate, 3 mg
      Dienogest and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing
      0.451 mg levomefolate calcium
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Area under the concentration vs time curve from zero to infinity for DNG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Maximum drug concentration for DNG and for E1, E2, E1S, and L-5-methyl-THF (baseline corrected and uncorrected)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-tlast)</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>AUC from time 0 to the last data point above the lower limit of quantitation for E1, E2, E1S, and L-5-methyl-THF (baseline corrected and uncorrected)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Time to reach maximum drug concentration in plasma for DNG and E1, E2, E1S, and L-5-methyl-THF (baseline uncorrected)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Half-life associated with the terminal slope for DNG and E1, E2, E1S, and L-5-methyl-THF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Apparent terminal rate constant(estimates only) for DNG and E1, E2, E1S, and L-5-methyl-THF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlast)</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>AUC from time 0 to the last data point above the lower limit of quantitation for DNG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Pre-dose and up to 72 hr post-dose for the treatments A and B and up to 12 hr post dose for the treatment C</time_frame>
    <description>Area under the concentration vs time curve from zero to infinity E1, E2, E1S, and L-5-methyl-THF (baseline corrected)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <arm_group>
    <arm_group_label>Estradiol + dienogest + levomefolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol + dienogest</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levomefolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium</intervention_name>
    <description>Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days</description>
    <arm_group_label>Estradiol + dienogest + levomefolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)</intervention_name>
    <description>Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days</description>
    <arm_group_label>Estradiol + dienogest</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY 86-7660,levomefolate calcium</intervention_name>
    <description>Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days</description>
    <arm_group_label>Levomefolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women, age: 45-75 years with body mass index between ≥18 and
             ≤30 kg/m2. Post-menopausal state revealed by: medical history, and hormone analyses in
             serum: estradiol ≤20 pg/mL and in women &lt;60 years old: follicle-stimulating hormone ≥
             40 IU/L at screening

        Exclusion Criteria:

          -  Contraindications for use of combined (Estradiolvalerate/Dienogest) contraceptive
             (e.g.history of venous/arterial thromboembolic disease)

          -  Regular intake of medication

          -  Clinically relevant findings (ECG, blood pressure, physical and gynaecological
             examination, laboratory examination)

          -  Smoking
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Nandrolone</mesh_term>
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Tetrahydrofolates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

